Next Article in Journal
Exhaled Hydrogen after Lactulose Hydrogen Breath Test in Patient with Duodenal Ulcer Disease—A Pilot Study for Helicobacter-pylori-Associated Gastroduodenal Disease
Previous Article in Journal
Phytochemical Profile, Antioxidant Activity, Anti-Hyperglycemic Effect and Toxicity Assessment of Ridolfia segetum (L.) Moris Extract
Previous Article in Special Issue
Targeting Ca2+ and Mitochondrial Homeostasis by Antipsychotic Thioridazine in Leukemia Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 13
Issue 1
10.3390/life13010043
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Parkia speciosa Hassk. Empty Pod Extract Prevents Cardiomyocyte Hypertrophy by Inhibiting MAPK and Calcineurin-NFATC3 Signaling Pathways

by
Nor Hidayah Mustafa
1,
Juriyati Jalil
1,
Mohammed S. M. Saleh
2,
Satirah Zainalabidin
3,
Ahmad Yusof Asmadi
4 and
Yusof Kamisah
2,*
1
Centre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia
2
Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia
3
Program of Biomedical Science, Centre of Applied and Health Sciences, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia
4
Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia, Kem Sungai Besi, Kuala Lumpur 57000, Malaysia
*
Author to whom correspondence should be addressed.
Life 2023, 13(1), 43; https://doi.org/10.3390/life13010043
Submission received: 24 October 2022 / Revised: 4 December 2022 / Accepted: 21 December 2022 / Published: 23 December 2022
(This article belongs to the Special Issue Biological Activities of Natural Products, Antipsychotics, and Novel Derivatives - Volume II)
Browse Figures
Versions Notes

Abstract

:
Cardiac hypertrophy is an early hallmark during the clinical course of heart failure. Therapeutic strategies aiming to alleviate cardiac hypertrophy via the mitogen-activated protein kinase (MAPK)/calcineurin-nuclear factor of activated T-cells (NFAT) signaling pathway may help prevent cardiac dysfunction. Previously, empty pod ethanol crude extract of Parkia speciosa Hassk was shown to demonstrate protective effects against cardiomyocyte hypertrophy. Therefore, the current study aimed to investigate the effects of various fractions of the plant ethanol extract on the MAPK/NFAT signaling pathway in angiotensin II (Ang II)-induced cardiomyocyte hypertrophy. Simultaneous treatment with ethyl acetate (EA) fraction produced the most potent antihypertrophic effect evidenced by the reduced release of B-type natriuretic peptide (BNP). Subsequently, treatment with the EA fraction (6.25, 12.5, and 25 μg/mL) prevented an Ang II-induced increase in cell surface area, hypertrophic factors (atrial natriuretic peptide and BNP), reactive oxygen species, protein content, and NADPH oxidase 4 expression in the cells. Furthermore, EA treatment attenuated the activation of the MAPK pathway and calcineurin-related pathway (GATA-binding protein 4 and NFATC3), which was similar to the effects of valsartan (positive control). Our findings indicate that the EA fraction prevents Ang II-induced cardiac hypertrophy by regulating the MAPK/calcineurin-NFAT signaling pathway.

1. Introduction

Heart failure has become a major global clinical problem that claimed approximately 17.9 million lives in 2019 [1]. Causes of heart failure, including long-standing hypertension and coronary artery disease, may arise from unhealthy dietary habits and a sedentary lifestyle [2]. Pathological cardiac hypertrophy is a prerequisite marker of heart failure. It is characterized by the thickening of cardiac muscle, leading to irreversible morphological and functional changes. Following the induction of the hypertrophic response, fetal cardiac genes—atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and β-myosin heavy chain—are activated. They are well-known cardiac hypertrophy biomarkers that increase with the progression of cardiac hypertrophy, ultimately causing heart failure [3]. Numerous mediators and signaling pathways are involved in the development of cardiac hypertrophy. The mitogen-activated protein kinase (MAPK) cascade comprises three major subfamilies: p38 kinase, c-Jun N-terminal protein kinase (JNK), and extracellular signal-regulated protein kinase (ERK1/2). The cascade produces reactive oxygen species (ROS) via NADPH oxidase (Nox) in the cardiovascular system; Nox plays a significant role in the pathogenesis of cardiac hypertrophy, with increased expression of Nox2 and Nox4 in cardiomyocytes [4,5]. Direct inhibition of the MAPK pathway significantly decreases cardiac hypertrophy [6,7,8]. Accumulating data demonstrate that the activation of the calcium-calcineurin pathway and its downstream target—nuclear factor of activated T cells (NFAT)—are well-established as central prohypertrophic factors in the regulation of myocardial hypertrophy [9]. Upon stimulation of the hypertrophic response, calcineurin dephosphorylates NFAT transcription factor, which then translocates into the nucleus to form a complex with GATA-binding protein 4 (GATA4), a key molecule modulating cardiac hypertrophy-related genes. The MAPK and calcium-calcineurin pathways serve as a key regulatory axis in cardiac hypertrophy, and they are involved in an interdependent network of signaling cascades [10,11,12].
Heart failure is clinically treated using various drugs, such as angiotensin receptor blockers, β-blockers, and angiotensin receptor-neprilysin inhibitors [13]. Extensive studies have been performed on medicinal plants, investigating their potential in reducing cardiac hypertrophy as an alternative to modern medicines. Extracts from Parkia speciosa Hassk. empty pods [14], Plantago asiatica L. seeds [15], and Centella asiatica (L.) Urb. [16] were demonstrated to decrease cardiac hypertrophy.
P. speciosa Hassk. (Fabaceae), also known as the bitter bean, is a perennial tree that grows abundantly in Southeast Asia. It is traditionally used to alleviate hypertension and maintain cardiovascular health [17]. The plant’s empty pod possesses diverse biological properties, including antioxidant [18], anti-inflammatory [19,20], hypotensive [21], and antidiabetic [22,23] properties. These properties have been associated with the presence of several compounds, including phenolic acids, tannins, flavonoids (e.g., gallic acid, ellagic acid, quercetin, rutin, gossypetin, and catechin), triterpenes, and polysaccharides [23,24]. The crude ethanol extract of this plant exhibits a protective effect against cardiomyocyte hypertrophy by modulating the MAPK signaling pathway and the angiotensin II (Ang II)/ROS/nitric oxide (Ang II/ROS/NO) axis [14]. However, the effects of its fractions on other signaling pathways involved in the pathogenesis of cardiac hypertrophy, such as the calcineurin-NFAT signaling pathway, remain unclear. Therefore, the present study explored the co-treatment effects of various fractions of P. speciosa empty pod ethanol extract on the regulation of the MAPK and calcineurin-NFAT signaling pathways in Ang II-induced cardiomyocyte hypertrophy.

2. Materials and Methods

2.1. Plant Collection and Sequential Extraction of Empty Pods

P. speciosa pods were collected from Kampung Kua, Ajil, Terengganu, Malaysia (5°00′01.8″ N 103°04′24.6″ E) in February 2020. The plant was authenticated by a botanist and deposited at the Universiti Kebangsaan Malaysia Herbarium (Voucher specimen: ID009/2020). Extraction of the pods was performed following the methods outlined by a previous study [23]. Briefly, they were peeled, deseeded, cut into small pieces, and freeze-dried for five days. The dried, empty pods were crushed into powder and extracted in ethanol in a 1:10 (w/v) ratio before being sonicated (320 W, 30 °C) for 1 h. The solution was then centrifuged (5 min, 10,000 rpm), filtered with Whatman filter paper, and the filtrate was vacuum-evaporated at 40 °C. A part of the crude extract was further fractionated with n-hexane, chloroform, ethyl acetate, and methanol according to polarity. The extracts were dried with a rotary vacuum evaporator and freeze-dryer before being stored at −80 °C until further use.

2.2. Cell Culture

The H9c2 cell line from rat embryonic myocardial ventricles was acquired from the American Type Culture Collection (ATCC CRL-1446, Rockville, MD, USA). The cells (passages 3–7) were cultured in high-glucose Dulbecco’s modified Eagle medium (DMEM) (Gibco, Grand Island, NY, USA) complemented with fetal bovine serum (10%, Gibco, Grand Island, NY, USA) and penicillin/streptomycin (1%, 100 IU/mL:100 µg/mL) in humidified air with 5% CO2 (37 °C). The cells were starved in serum-free DMEM for 24 h before treatment.

2.3. Cell Viability Measurement

Cell viability was estimated using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulphenyl)-2H-tetrazolium assay (Promega, Madison, WI, USA). H9c2 cells (1 × 105 cells/dish) were exposed to various concentrations of crude ethanol extract and n-hexane, chloroform, ethyl acetate, and methanol fractions for 24 h. The fractions were liquefied in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO, USA), with a final culture concentration of the solvent being less than 0.001%.

2.4. Antihypertrophic Screening of Extract Fractions

The potential antihypertrophic effect of the crude extract and various P. speciosa empty pod fractions was screened in H9c2 cardiomyocytes that were co-incubated with 1 µM Ang II [25] for 24 h. The concentrations of the extract and fractions we used were lower than their respective IC50 values. BNP level was determined using a commercial assay kit (Elabscience, Houston, TX, USA) to assess cell hypertrophy, calculated against a standard curve. The fraction that exhibited the highest antihypertrophic property was selected for subsequent experiments to elucidate its cardioprotective mechanisms.

2.5. Chromatography Analysis

Phytochemical profiling of the ethyl acetate fraction was performed using highly sensitive ultra-high-performance liquid chromatography-quadrupole time of flight-mass spectrometry (UHPLC-QTOF-MS) following a previously described method [23]. Chromatography analysis was performed using an Agilent 1290 Infinity II UPLC System (Agilent Technologies Santa Clara, CA, USA) and 6550 iFunnel Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA, USA) equipped with a C18 column (100 mm × 2.1 mm I.D.; 3-µm particle size) (Agilent Technologies, Santa Clara, CA, USA). Samples were eluted with 0.1% aqueous formic acid solution and methanol at 0.4 mL/min. The negative ion mode was selected due to its high selectivity and sensitivity for further liquid chromatography-mass spectrometry (LC-MS) analysis.

2.6. Experimental Groups

H9c2 cells (1 × 105 cells/dish) were randomly divided into seven groups. Five groups were exposed to 1 µM Ang II (Sigma Aldrich, St Louis, MO, USA) [25]; three of these groups were co-treated with different concentrations of ethyl acetate fraction (6.25, 12.5, and 25 µg/mL) from the empty pod extract, and another group was co-treated with valsartan (20 μM) [26] as the positive control. The fraction and valsartan were dissolved in 0.001% DMSO. A group treated with vehicle (0.001% DMSO) served as the control, and another group was incubated with 25 µg/mL ethyl acetate fraction of the extract. Incubation with the respective treatments was performed for 24 h.

2.7. Cell Size Measurement

Briefly, H9c2 cells were inoculated in six-well plates (1 × 104 cells/well). At the end of treatment, the cells were rinsed with phosphate-buffered saline (PBS). The cells were affixed with paraformaldehyde (4%) before being dyed with 0.5% crystal violet in ethanol (2%) [27]. The cross-sectional surface area of a minimum of ten representative cells from three wells were averaged and recorded as one n value. The area was quantified using Image J software (U. S. National Institutes of Health, Bethesda, MD, USA) and expressed as a ratio of the control cells.

2.8. Protein Content Assay

Protein content was measured as described previously [27,28]. H9c2 cells were lysed with radioimmunoprecipitation assay (RIPA) buffer before their protein content was estimated using a commercial kit (BioRad Laboratories, Hercules, CA, USA) and expressed as mg protein per 105 cells.

2.9. ROS Assay

ROS production was measured using a 2′7′-dichlorodihydrofluorescein diacetate (DCFH-DA) cellular ROS detection assay kit (ab113851, Abcam, Cambridge, UK). H9c2 cells from each group were incubated with 20 µM DCFH-DA for 30 min at 37 °C in the dark. The cells were rinsed thrice before visualization under a fluorescence microscope (Olympus Optical, Tokyo, Japan) at 100× magnification. The cell intensity from six arbitrarily chosen areas was evaluated using ImageJ software (US National Institutes of Health, Bethesda, MD, USA).

2.10. NADPH Oxidase 4 (Nox4) Immunofluorescence Assay

To determine Nox4 expression, 24 h after treatment, the cells were affixed with paraformaldehyde (4%) in PBS at room temperature for 15 min before being permeabilized with 0.1% Triton X-100/0.1% sodium citrate for 20 min. The cells were blocked with bovine serum albumin (5%) and incubated with Nox4 antibody (1:200; sc-518092, Santa Cruz Biotechnology, Dallas, TX, United States) diluted in 1% skimmed milk solution overnight. Then, the cells were incubated with Alexa Fluor 488 goat anti-mouse antibody (1:200; A-11059, Invitrogen, Waltham, MA, USA) for 1 h and rinsed with PBS. The cellular nuclei were stained blue with 4′,6-diamidino-2-phenylindole (DAPI; ab228549, Abcam, Cambridge, MA, USA) and analyzed under a fluorescence microscope (Olympus Optical, Tokyo, Japan).

2.11. ANP and NFATC3 Gene Expression Assay

TRIzol reagent (Sigma-Aldrich, St. Louis, MO, USA) was used to extract total RNA from H9c2 cells 24 h after treatment. Then, 1 µg of total RNA was reverse-transcribed using ReverTra AceTM qPCR RTMaster Mix with gDNA Remover (FSQ-301; Toyobo, Japan) to obtain complementary DNA. RNA levels of ANP and NFATC3 in H9c2 cells were quantified using SYBR Green PCR Master Mix Kit (QPS-201; Toyobo, Japan). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was employed as an in-house control. A quantitative reverse transcription polymerase chain reaction (RT-qPCR) was conducted using a CFX96TM Real-Time System (Bio-Rad Laboratories, CA, USA) for 60 cycles. The sequences of primers for amplification were: ANP, 5′-GGTAGGATTGACAGGATTGGA-3′ and 5′-GCAGATTTGGCTGTTATCTTCG-3′; NFATC3, 5′-GGAAATCCCACTTCTACCTGAA-3′ and 5′-GCCAATATCAGTTTCTCCTTTTCG-3′, and GAPDH, 5′-AACCCATCACCATCTTCCAG-3′ and 5′-CCAGTAGACTCCACGACATAC-3′. Cycle threshold (Ct) values were used to measure the amount of amplified PCR product relative to GAPDH as the control.

2.12. Protein Expression

The expression of proteins of interest was analyzed via western blotting. After treatment, cells were lysed in RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA) containing a protease inhibitor cocktail (Roche, Basel, Switzerland) and phosphatase inhibitor (Roche, Basel, Switzerland). The protein content in supernatants obtained after 30 min of centrifugation at 14,000 rpm (4 °C) was quantified by using a Bradford assay (Sigma Aldrich, St. Louis, MO, USA). Proteins (30 μg) were applied to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10–12%) and then moved to polyvinylidene fluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA, USA). Membrane blocking was performed for 1 h using 5% w/v bovine serum albumin or 5% skimmed milk powder in 1% Tris-buffered saline/1% Tween 20. Subsequently, the PVDF membranes were incubated overnight at 4 °C with primary antibodies against phosphorylated p38 (p-p38, 1:1000; sc-166182, Santa Cruz Biotechnology, Dallas, TX, USA), phosphorylated ERK (p-ERK, 1:1000; #4377; Cell Signaling Technology, Danvers, MA, USA), phosphorylated JNK (p-JNK, 1:500; ab4821, Abcam, Cambridge, UK), phosphorylated GATA4 (p-GATA4, 1:1000; sc-32823, Santa Cruz Biotechnology, Dallas, TX, USA), calcineurin (1:1000; ab71149, Abcam, Cambridge, UK), Nox4 (1:1000; sc-518092, Santa Cruz Biotechnology, Dallas, TX, USA), and β-actin (1:1000; sc-47778, Santa Cruz Biotechnology, Dallas, TX, USA). After meticulous washing, the membranes were incubated with horseradish peroxidase-conjugated IgG secondary antibody (1:3000; anti-mouse 7076P2; anti-rabbit 7074S; Cell Signaling Technology, Danvers, MA, USA) for 1 h at room temperature. The bands were visualized via enhanced chemiluminescence developing solution (Bio-Rad, Hercules, CA, USA) using a gel documentation system (AI600RGB, GE Healthcare Japan Corporation, Tokyo, Japan). The bands were then quantified using ImageJ software (US National Institutes of Health, Bethesda, MD, USA).

2.13. Statistical Analysis

The Shapiro–Wilk test was used to assess the data distribution. The data were analyzed using one-way analysis of variance and Tukey’s post-hoc test using SPSS v24.0 software (IBM Corp., Armonk, NY, USA). Data are presented as mean ± standard error of the mean (SEM) from a minimum three independent triplicate assays. The accepted statistically significant value was p < 0.05.

3. Results

3.1. Cell Cytotoxicity and Antihypertrophic Screening of Fractions

The median inhibitory concentration (IC50) of the crude extract, n-hexane, chloroform, ethyl acetate, and methanol fractions was approximately 216.69 ± 5.66 µg/mL, 114.88 ± 7.46 µg/mL, 62.58 ± 3.29 µg/mL, 315.88 ± 4.92 µg/mL, and 531.92 ± 6.36 µg/mL, respectively (Figure 1). Preliminary antihypertrophic screening of extracts with cellular BNP levels demonstrated significantly increased antihypertrophic activity with crude (25 µg/mL), ethyl acetate (25 µg/mL), and methanol (100 and 200 µg/mL) fractions compared with the Ang II group (Figure 2). Based on these findings, an ethyl acetate fraction at 25 µg/mL was selected for subsequent experiments.

3.2. UHPLC-QTOF-MS/MS Identification

The total ion chromatogram profile of the ethyl acetate fraction of P. speciosa empty pods is depicted in Figure 3. Based on the MS/MS database library, 19 compounds were characterized and predicted from the ethyl acetate fraction, including gallic acid, picein, amaronol A, and quercetin (Table 1). Most of the compounds were flavonoids.

3.3. Ethyl Acetate Fraction Inhibited Ang-II Induced Cardiomyocyte Hypertrophy

Ang II significantly enhanced the expansion of cell surface area (Figure 4). The effect was significantly decreased following treatment with various concentrations of ethyl acetate fraction of P. speciosa and valsartan. No significant difference was noted among the treated groups.

3.4. Ethyl Acetate Fraction Inhibited Ang II-Induced Increased Total Protein Content and ANP Expression

Exposure to Ang II increased the total protein content (Figure 5a). The effect was significantly inhibited in the presence of ethyl acetate fraction and valsartan. No differences were noted among the treated groups. Furthermore, Ang II exposure increased the expression of fetal cardiac gene ANP in H9c2 cardiomyocytes (Figure 5b). Co-incubation with various concentrations of ethyl acetate fraction reduced this increase in a concentration-dependent manner. Moreover, valsartan exerted a significant protective effect on the parameter. The expression of ANP in the ethyl acetate fraction-treated groups, except for the lowest concentration (6.25 µg/mL), was significantly lower than in the valsartan group.

3.5. Ethyl Acetate Fraction Suppressed Ang II-Induced Intracellular ROS Generation

Ang II significantly increased intracellular ROS levels (Figure 6). Both the ethyl acetate fraction and valsartan reduced the Ang II-induced increase in ROS generation.

3.6. Ethyl Acetate Fraction Suppressed Ang II-Induced Nox4 Expression

Ang II significantly increased Nox4 expression in H9c2 cardiomyocytes. The effects were inhibited by the ethyl acetate fraction and valsartan (Figure 7a). A similar observation was made with Nox4 immunofluorescence (Figure 7b). Nox4 expression was detected in the membrane, cytoskeleton, and nucleus. Induction by Ang II significantly intensified the fluorescence of Nox4 (green), while treatment with the ethyl acetate fraction decreased fluorescence.

3.7. Effect of Ethyl Acetate Fraction on Ang II-Induced MAPK Signaling Pathway Activation

Ang II induced a marked increase in the expression of p-p38, p-JNK, and p-ERK1/2 (Figure 8). Treatment with the ethyl acetate fraction attenuated the increased p-p38 and p-JNK induced by Ang II in a concentration-dependent manner (Figure 8a,b). The expression of p-ERK1/2 was similarly attenuated in the groups treated with different concentrations of ethyl acetate fraction (Figure 8c). The group treated with valsartan exhibited significant protective effects on p-p38, p-JNK, and p-ERK1/2 expression but had a remarkably lower p-p38 and p-ERK1/2 expression than the group treated with the lowest concentration of ethyl acetate fraction (6.25 µg/mL).

3.8. Effect of Ethyl Acetate Fraction on Ang II-Induced Calcineurin Related Pathway Activation

Ang II increased protein expression of p-GATA4 in H9c2 cells (Figure 9a). Treatment with ethyl acetate fraction reduced the detrimental effect of Ang II on p-GATA4 in a concentration-dependent manner. Furthermore, valsartan inhibited Ang II-induced p-GATA expression, and the expression was remarkably lower than in the groups treated with the 6.25 µg/mL and 12.5 µg/mL ethyl acetate fraction.
Ang II significantly increased calcineurin protein expression, which was reduced by treatment with ethyl acetate fraction and valsartan (Figure 9b). No difference was noted between treatment groups. A similar finding was observed with NFATC3 gene expression, where Ang II increased expression, and the effect was inhibited by the ethyl acetate fraction and valsartan (Figure 9c).

4. Discussion

In the current study, crude ethanol extract of P. speciosa empty pods and its ethyl acetate and methanol fractions exhibited antihypertrophic properties in H9c2 cardiomyocytes exposed to Ang II. The ethyl acetate fraction exhibited the most intense effect. The findings suggest that the bioactive constituents responsible for the effect were semipolar and polar compounds, which could be phenolics, flavonoids, and terpenoids, which were putatively identified by UHPLC-QTOF-MS/MS. In a previous study, a different set of metabolites was identified using a similar chromatography method in crude ethanol extracts of P. speciosa empty pods collected from the same site [23]. Theaflavin, myricitrin, curcumin, and tremulacin were additionally identified. Previous studies have reported the antioxidant and anti-inflammatory properties of ethyl acetate fraction of the empty pods in human umbilical vein endothelial cells and cardiomyocytes [18,19,20]. Quercetin was also detected in the fraction [18,20]. Quercetin 3′-glucoside and quercetin 3-(6‴-sinapylglucosyl)(1->2)-galactoside were putatively identified in the ethyl acetate fraction of the present study. Oxidative stress and inflammation play a prominent role in the development of myocardial hypertrophy [29]. However, the cardioprotective effect of the ethyl acetate fraction was not seen at the highest concentration (200 µg/mL). It was possible that the concentration might have posed a toxic effect, manifested in the increase in cell size. Moreover, the number of viable cells at the concentration was reduced to approximately 80%. On the other hand, the cardioprotective effects of the methanol fraction at higher concentrations were investigated at 100–300 µg/mL. It also demonstrated protective effects against Ang II on cell surface area, total protein content, and intracellular ROS level (Figures S1–S3), which were comparable to those of ethyl acetate fraction.
The protective effect of the ethyl acetate fraction against Ang II-induced cardiomyocyte hypertrophy was evidenced by decreased cell surface area, protein content, and ANP expression. These are typical features of cardiac hypertrophy [27,30]. The increase in protein content occurs due to increased myocardial RNA content, leading to cardiac hypertrophy in animals exposed to pressure overload [31]. Hypertrophy activates multiple fetal cardiac genes, including ANP and BNP, causing their release in response to augmented volume-mediated stretch of the myocardial cells [32]. The fraction exerted better inhibitory effect than valsartan on ANP expression, proposing the protective mechanism was partially different from that of valsartan, likely not via Ang II type 1 receptor blockade. ANP-converting enzyme (corin) activates inactive pro-ANP into ANP in the heart, while zymogen corin is activated by proprotein convertase subtilisin/kexin type 6 (PCSK6) [33]. The expression of PCSK6 was reported to be elevated in experimental myocardial infarction-induced cardiac remodeling [34]. Therefore, it is possible that the fraction decreased the activity of PCSK6, resulting in the reduced activity of corin and finally the downregulation of ANP expression. However, the postulation needs to be investigated and confirmed in future studies.
The findings of the current study suggest that the ethyl acetate fraction of P. speciosa empty pods effectively inhibits cardiomyocyte hypertrophic responses, and this effect was similarly reported with the crude ethanol extract [14]. The antihypertrophic activity of the crude extract was believed to be mediated by the presence of rutin and quercetin, which were detected by HPLC [14]. However, rutin was not one of the tentatively identified compounds in the ethyl acetate fraction in our study, possibly due to the difference in chromatography methods used in our study. Rutin decreased Ang II-induced cardiomyocyte hypertrophy to a similar extent as quercetin, but at a lower concentration (50 µM versus 331 µM, respectively) [35].
ROS serves as a second messenger and is perceived as a crucial trigger for cardiac hypertrophy, which eventually progresses to heart failure [36]. ROS is produced via Nox activation upon Ang II binding to Ang II type 1 receptor. Nox4 is an important mediator in the pathogenesis of heart disease. The isoform is the principal generator of mitochondrial ROS, which mediates cardiac dysfunction [37]. In the present study, the ethyl acetate fraction significantly mitigated Ang II-induced Nox4 expression and decreased the generation of intracellular ROS in cardiomyocytes, likely via the antioxidant activity of the fraction, which was reported by Gui et al. [18]. Valsartan likewise exerted antioxidant effects, as previously reported [14].
Accumulating data have suggested that the MAPK cascade is activated by ROS in cardiomyocyte hypertrophy [38,39]. The MAPK signaling cascade is initiated by the activation of G protein-coupled receptor kinases, leading to phosphorylation of multiple intracellular targets and transcription factors by the downstream members of MAPK family, namely p38, JNK, and ERK1/2 [14]. The downregulation of phosphorylated p38, JNK, and ERK expression by the ethyl acetate fraction indicated its ability to attenuate Ang II-induced activation of the MAPK signaling cascade, leading to a reduction in cardiomyocyte hypertrophy. We postulate that the fraction diminished ROS generation via its antioxidant action, leading to the inhibition of the MAPK pathway. Activated MAPK signaling implies increased inflammation [40], suggestive of anti-inflammatory property of the compounds present in the fraction. A similar inhibition of the MAPK signaling pathway by P. speciosa empty pod crude extract was recently reported [14].
Upon the activation of the hypertrophic response, calcineurin activated by the presence of elevated cytosolic calcium concentration promotes dephosphorylation of p-NFATC3 and other transcription factors. NFATC3 forms a complex with GATA4, which then activates downstream transcription factors and fetal genes, such as BNP and ANP [39,41]. Treatment with the ethyl acetate fraction inhibited the increase in the expression of calcineurin, NFATC3, and p-GATA4 induced by Ang II, indicating that its cardioprotective activity may occur in part via a calcineurin-related pathway. There are no reports regarding the effects of P. speciosa empty pod extract on calcineurin. Physiologically, calcineurin participates in various cellular processes, including immunomodulation and cardiomyocyte maturation. However, pathologically, the activation of NFAT by calcineurin induces the activation of T cells and tumor necrosis factor α in addition to hypertrophic gene transcription, leading to pathological hypertrophy and initiation of the inflammatory process in cardiomyocytes [41]. Therefore, it can be hypothesized that the fraction inhibited the development of the inflammatory process and subsequently inhibited hypertrophic events. Moreover, GATA4 is one of the myocardial hypertrophic growth regulators [39]. Therefore, the inhibitory effect of the ethyl acetate fraction on GATA4 activation confirmed its antihypertrophic activity. Figure 10 summarizes the protective effects of ethyl acetate fraction co-treatment against cardiac hypertrophy via MAPK and calcineurin-NFAT-GATA4 signaling pathway activation. Therefore, the findings of the current study provide a basis for future studies that may identify new therapeutic targets in preventing cardiac hypertrophy.
In general, the ethyl acetate fraction did not exhibit significant concentration-dependent effects, except for the effect on ANP expression. The beneficial effects of the fraction were comparable to those of valsartan, a drug that has been used clinically to reduce cardiac remodeling and its progression to heart failure [42]. Numerous studies have demonstrated the antihypertrophic properties of some of the compounds that might be present in the fraction, such as gallic acid [43], quercetin [14], epigallocatechin-3-gallate [44], kaempferol [45], luteolin [46], and herbacetin [47].
A limitation of the current study was that the phytochemical profile of the fraction was only presumptive. However, it is believed that the protective effects observed in the study might be attributable to the presence of various bioactive compounds in the fraction. The compounds might exert synergistic effects.

5. Conclusions

The ethyl acetate fraction of P. speciosa empty pods attenuated Ang II-induced cardiomyocyte hypertrophy via its antioxidant and anti-inflammatory properties by suppressing Nox-4-associated ROS production and downregulating MAPK and calcineurin-NFAT signaling pathways. The protective effects might be attributable to the presence of flavonoids in the empty pods.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/life13010043/s1, Figure S1: Effects of the ethyl acetate (EA) and methanol (MeOH) fractions (µg/mL) of P. speciosa and valsartan (20 µM) on cell surface area in Ang II-induced cardiomyocyte hypertrophy.; Figure S2: Effects of the ethyl acetate (EA) and methanol (MeOH) fractions (µg/mL) of P. speciosa and valsartan (20 µM) on protein content per cell (mg/million cells) in Ang II-induced cardiomyocyte hypertrophy; Figure S3: Effects of the ethyl acetate (EA) and methanol (MeOH) fractions (µg/mL) of P. speciosa and valsartan (20 µM) on reactive oxygen species (ROS) in Ang II-induced cardiomyocyte hypertrophy.

Author Contributions

All authors designed the study, approved the final version of the manuscript. N.H.M. conducted the experiments, analyzed the data and drafted the manuscript. J.J. and Y.K. supervised the experiments. Y.K. revised the manuscript and obtained the funding. J.J., S.Z., A.Y.A. and M.S.M.S. reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

The study was funded by the Ministry of Higher Education of Malaysia (FRGS-1-2019-SKK10-UKM-02-1).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

The authors would like to express the appreciation to Siti Khadijah Sulaiman, Nor Nadirah Abdullah, Nur Syahidah Nor Hisam, Nur Syakirah Othman, Noor Baitee A Rahim, Manali Haniti Mohd Zahid, Fadhlullah Zuhair Japar Sidek, and Juliana Abd Hamid for their excellent technical assistance.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mascolo, A.; di Mauro, G.; Cappetta, D.; De Angelis, A.; Torella, D.; Urbanek, K.; Berrino, L.; Nicoletti, G.F.; Capuano, A.; Rossi, F. Current and future therapeutic perspective in chronic heart failure. Pharmacol. Res. 2022, 175, 106035. [Google Scholar] [CrossRef] [PubMed]
  2. Ng, C.Y.; Leong, X.F.; Masbah, N.; Adam, S.K.; Kamisah, Y.; Jaarin, K. Heated vegetable oils and cardiovascular disease risk factors. Vasc. Pharmacol. 2014, 61, 1–9, reprinted in Vascul. Pharmacol. 2014, 62, 38–46. [Google Scholar] [CrossRef] [PubMed]
  3. Siti, H.N.; Jalil, J.; Asmadi, A.Y.; Kamisah, Y. Roles of rutin in cardiac remodeling. J. Funct. Foods 2020, 64, 103606. [Google Scholar] [CrossRef]
  4. Szekeres, F.L.M.; Walum, E.; Wikström, P.; Arner, A. A small molecule inhibitor of Nox2 and Nox4 improves contractile function after ischemia-reperfusion in the mouse heart. Sci. Rep. 2021, 11, 11970. [Google Scholar] [CrossRef]
  5. Lee, C.Y.; Park, H.K.; Lee, B.S.; Jeong, S.; Hyun, S.A.; Choi, J.W.; Kim, S.W.; Lee, S.; Lim, S.; Hwang, K.C. Novel therapeutic effects of pterosin B on Ang II-induced cardiomyocyte hypertrophy. Molecules 2020, 25, 5279. [Google Scholar] [CrossRef]
  6. Ba, L.; Gao, J.; Chen, Y.; Qi, H.; Dong, C.; Pan, H.; Zhang, Q.; Shi, P.; Song, C.; Guan, X.; et al. Allicin attenuates pathological cardiac hypertrophy by inhibiting autophagy via activation of P3K/AKT/mTOR and MAPK/ERK/mTOR signaling pathways. Phytomedicine 2019, 58, 152765. [Google Scholar] [CrossRef]
  7. Dong, B.; Liu, C.; Xue, R.; Wang, Y.; Sun, Y.; Liang, Z.; Fan, W.; Jiang, J.; Zhao, J.; Su, Q.; et al. Fisetin inhibits cardiac hypertrophy by suppressing oxidative stress. J. Nutr. Biochem. 2018, 62, 221–229. [Google Scholar] [CrossRef]
  8. Liao, H.H.; Zhang, N.; Meng, Y.Y.; Feng, H.; Yang, J.J.; Li, W.J.; Chen, S.; Wu, H.M.; Deng, W.; Tang, Q.Z. Myricetin alleviates pathological cardiac hypertrophy via TRAF6/TAK1/MAPK and Nrf2 signaling pathway. Oxidative Med. Cell. Longev. 2019, 2019, 6304058. [Google Scholar] [CrossRef]
  9. Yin, Z.; Wang, X.; Zhang, L.; Zhou, H.; Wei, L.; Dong, X. Aspirin attenuates angiotensin II-induced cardiomyocyte hypertrophy by inhibiting the Ca2+/calcineurin-NFAT signaling pathway. Cardiovasc. Ther. 2016, 34, 21–29. [Google Scholar] [CrossRef] [Green Version]
  10. Lin, K.H.; Shibu, M.A.; Peramaiyan, R.; Chen, Y.F.; Shen, C.Y.; Hsieh, Y.L.; Chen, R.J.; Viswanadha, V.P.; Kuo, W.W.; Huang, C.Y. Bioactive flavone fisetin attenuates hypertension associated cardiac hypertrophy in H9c2 Cells and in spontaneously hypertension rats. J. Funct. Foods 2019, 52, 212–218. [Google Scholar] [CrossRef]
  11. Luo, Y.; Jiang, N.; May, H.I.; Luo, X.; Ferdous, A.; Schiattarella, G.G.; Chen, G.; Li, Q.; Li, C.; Rothermel, B.A.; et al. Cooperative binding of ETS2 and NFAT links Erk1/2 and calcineurin signaling in the pathogenesis of cardiac hypertrophy. Circulation 2021, 144, 34–51. [Google Scholar] [CrossRef] [PubMed]
  12. Wang, C.H.; Pandey, S.; Sivalingam, K.; Shibu, M.A.; Kuo, W.W.; Yu, L.; Viswanadha, V.P.; Lin, Y.C.; Liao, S.C.; Huang, C.Y. Leech extract: A candidate cardioprotective against hypertension-induced cardiac hypertrophy and fibrosis. J. Ethnopharmacol. 2021, 264, 113346. [Google Scholar] [CrossRef] [PubMed]
  13. Mustafa, N.H.; Jalil, J.; Zainalabidin, S.; Saleh, M.S.M.; Asmadi, A.Y.; Kamisah, Y. Molecular mechanisms of sacubitril/valsartan in cardiac remodeling. Front. Pharmacol. 2022, 13, 892460. [Google Scholar] [CrossRef]
  14. Siti, H.N.; Jalil, J.; Asmadi, A.Y.; Kamisah, Y. Parkia speciosa Hassk. empty pod extract alleviates angiotensin II-induced cardiomyocyte hypertrophy in H9c2 cells by modulating the Ang II/ROS/NO axis and MAPK pathway. Front. Pharmacol. 2021, 12, 741623. [Google Scholar] [CrossRef] [PubMed]
  15. Fan, W.; Zhang, B.; Wu, C.; Wu, H.; Wu, J.; Wu, S.; Zhang, J.; Yang, X.; Yang, L.; Hu, Z.; et al. Plantago asiatica L. seeds extract protects against cardiomyocyte injury in isoproterenol-induced cardiac hypertrophy by inhibiting excessive autophagy and apoptosis in mice. Phytomedicine 2021, 91, 153681. [Google Scholar] [CrossRef]
  16. Ding, B.; Niu, W.; Wang, S.; Zhang, F.; Wang, H.; Chen, X.; Chen, S.; Ma, S.; Kang, W.; Wang, M.; et al. Centella asiatica (L.) Urb. attenuates cardiac hypertrophy and improves heart function through multi-level mechanisms revealed by systems pharmacology. J. Ethnopharmacol. 2022, 291, 115106. [Google Scholar] [CrossRef]
  17. Saleh, M.S.M.; Jalil, J.; Zainalabidin, S.; Asmadi, A.Y.; Mustafa, N.H.; Kamisah, Y. Genus Parkia: Phytochemical, medicinal uses, and pharmacological properties. Int. J. Mol. Sci. 2021, 22, 618. [Google Scholar] [CrossRef]
  18. Gui, J.S.; Mustafa, N.H.; Jalil, J.; Jubri, Z.; Kamisah, Y. Modulation of Nox4 and MAPK signaling pathways by Parkia speciosa empty pods in H9c2 cardiomyocytes exposed to H2O2. Indian J. Pharm. Sci. 2019, 81, 1029–1035. [Google Scholar] [CrossRef]
  19. Gui, J.S.; Jalil, J.; Jubri, Z.; Kamisah, Y. Parkia speciosa empty pod extract exerts anti-inflammatory properties by modulating NFκB and MAPK pathways in cardiomyocytes exposed to tumor necrosis factor-α. Cytotechnology 2019, 71, 79–89. [Google Scholar] [CrossRef]
  20. Mustafa, N.H.; Ugusman, A.; Jalil, J.; Kamisah, Y. Anti-inflammatory property of Parkia speciosa empty pod extract in human umbilical vein endothelial cells. J. Appl. Pharm. Sci. 2018, 8, 152–158. [Google Scholar]
  21. Kamisah, Y.; Zuhair, J.S.F.; Juliana, A.H.; Jaarin, K. Parkia speciosa empty pod prevents hypertension and cardiac damage in rats given N(G)-nitro-L-arginine methyl ester. Biomed. Pharmacother. 2017, 96, 291–298. [Google Scholar] [CrossRef] [PubMed]
  22. Gao, L.; Zhang, W.; Yang, L.; Fan, H.; Olatunji, O.J. Stink bean (Parkia speciosa) empty pod: A potent natural antidiabetic agent for the prevention of pancreatic and hepatorenal dysfunction in high fat diet/streptozotocin-induced type 2 diabetes in rats. Arch. Physiol. Biochem. 2021, 1–7. [Google Scholar] [CrossRef] [PubMed]
  23. Saleh, M.S.M.; Jalil, J.; Mustafa, N.H.; Ramli, F.F.; Asmadi, A.Y.; Kamisah, Y. UPLC-MS-based metabolomics profiling for α-glucosidase inhibiting property of Parkia speciosa pods. Life 2021, 11, 78. [Google Scholar] [CrossRef]
  24. Ko, H.J.; Ang, L.H.; Ng, L.T. Antioxidant activities and polyphenolic constituents of bitter bean Parkia speciosa. Int. J. Food Prop. 2014, 17, 1977–1986. [Google Scholar] [CrossRef] [Green Version]
  25. Singh, K.; Gupta, A.; Sarkar, A.; Gupta, I.; Rana, S.; Sarkar, S.; Khan, S. Arginyltransferase knockdown attenuates cardiac hypertrophy and fibrosis through TAK1-JNK1/2 Pathway. Sci Rep. 2020, 10, 598. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Al-Mazroua, H.A.; Al-Rasheed, N.M.; Korashy, H.M. Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: A novel mechanism of cardioprotection. J. Cardiovasc. Pharmacol. 2013, 61, 337–344. [Google Scholar] [CrossRef]
  27. Riaz, S.; Abdulrahman, N.; Uddin, S.; Jabeen, A.; Gadeau, A.P.; Fliegel, L.; Mraiche, F. Anti-hypertrophic effect of Na+/H+ exchanger-1 inhibition is mediated by reduced cathepsin B. Eur. J. Pharmacol. 2020, 888, 173420. [Google Scholar] [CrossRef]
  28. Wang, H.; Jessup, J.A.; Lin, M.S.; Chagas, C.; Lindsey, S.H.; Groban, L. Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2. Lewis rats. Cardiovasc. Res. 2012, 94, 96–104. [Google Scholar] [CrossRef] [Green Version]
  29. Ramli, F.F.; Hashim, S.A.S.; Raman, B.; Mahmod, M.; Kamisah, Y. Role of trientine in hypertrophic cardiomyopathy: A review of mechanistic aspects. Pharmaceuticals 2022, 15, 1145. [Google Scholar] [CrossRef]
  30. Xu, X.; Wang, J.; Wang, X. Silencing of circHIPK3 inhibits pressure overload-induced cardiac hypertrophy and dysfunction by sponging miR-185-3p. Drug Des. Devel. Ther. 2020, 14, 5699–5710. [Google Scholar] [CrossRef]
  31. Nagai, R.; Low, R.B.; Stirewalt, W.S.; Alpert, N.R.; Litten, R.Z. Efficiency and capacity of protein synthesis are increased in pressure overload cardiac hypertrophy. Am. J. Physiol. 1988, 255, H325–H328. [Google Scholar] [CrossRef] [PubMed]
  32. Fu, S.; Ping, P.; Wang, F.; Luo, L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J. Biol. Eng. 2018, 12, 2. [Google Scholar] [CrossRef] [Green Version]
  33. Forte, M.; Madonna, M.; Schiavon, S.; Valenti, V.; Versaci, F.; Zoccai, G.B.; Frati, G.; Sciarretta, S. Cardiovascular pleiotropic effects of natriuretic peptides. Int. J. Mol. Sci. 2019, 20, 3874. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Kuhn, T.C.; Knobel, J.; Burkert-Rettenmaier, S.; Li, X.; Meyer, I.S.; Jungmann, A.; Sicklinger, F.; Backs, J.; Lasitschka, F.; Müller, O.J.; et al. Secretome analysis of cardiomyocytes identifies PCSK6 (proprotein convertase subtilisin/kexin type 6) as a novel player in cardiac remodeling after myocardial infarction. Circulation 2020, 141, 1628–1644. [Google Scholar] [CrossRef] [PubMed]
  35. Siti, H.N.; Jalil, J.; Asmadi, A.Y.; Kamisah, Y. Rutin modulates MAPK pathway differently from quercetin in angiotensin II-induced H9c2 cardiomyocyte hypertrophy. Int. J. Mol. Sci. 2021, 22, 5063. [Google Scholar] [CrossRef] [PubMed]
  36. Togliatto, G.; Lombardo, G.; Brizzi, M.F. The future challenge of reactive oxygen species (ROS) in hypertension: From bench to bed side. Int. J. Mol. Sci. 2017, 18, 1988. [Google Scholar] [CrossRef] [Green Version]
  37. Zeng, S.Y.; Yang, L.; Lu, H.Q.; Yan, Q.J.; Gao, L.; Qin, X.P. Rutaecarpine prevents hypertensive cardiac hypertrophy involving the inhibition of Nox4-ROS-ADAM17 pathway. J. Cell. Mol. Med. 2019, 23, 4196–4207. [Google Scholar] [CrossRef]
  38. Chiang, C.J.; Chao, Y.P.; Ali, A.; Day, C.H.; Ho, T.J.; Wang, P.N.; Lin, S.C.; Padma, V.V.; Kuo, W.W.; Huang, C.Y. Probiotic Escherichia coli Nissle inhibits IL-6 and MAPK-mediated cardiac hypertrophy during STZ-induced diabetes in rats. Benef. Microbes 2021, 12, 283–293. [Google Scholar] [CrossRef]
  39. Yoon, J.J.; Son, C.O.; Kim, H.Y.; Han, B.H.; Lee, Y.J.; Lee, H.S.; Kang, D.G. Betulinic Acid protects Dox-triggered cardiomyocyte hypertrophy response through the GATA-4/Calcineurin/NFAT pathway. Molecules 2020, 26, 53. [Google Scholar] [CrossRef]
  40. Yang, N.; Zou, C.; Luo, W.; Xu, D.; Wang, M.; Wang, Y.; Wu, G.; Shan, P.; Liang, G. Sclareol attenuates angiotensin II-induced cardiac remodeling and inflammation via inhibiting MAPK signaling. Phytother. Res. 2022. [Google Scholar] [CrossRef]
  41. Chen, L.; Song, M.; Yao, C. Calcineurin in development and disease. Genes Dis. 2021, 9, 915–927. [Google Scholar] [CrossRef] [PubMed]
  42. Papadimitriou, L.; Hamo, C.E.; Butler, J. Heart Failure Guidelines on Pharmacotherapy. In Handbook of Experimental Pharmacology; Springer: Berlin/Heidelberg, Germany, 2017; Volume 243, pp. 109–129. [Google Scholar]
  43. Jin, L.; Piao, Z.H.; Sun, S.; Liu, B.; Kim, G.R.; Seok, Y.M.; Lin, M.Q.; Ryu, Y.; Choi, S.Y.; Kee, H.J.; et al. Gallic acid reduces blood pressure and attenuates oxidative stress and cardiac hypertrophy in spontaneously hypertensive rats. Sci. Rep. 2017, 7, 15607. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Cai, Y.; Yu, S.S.; He, Y.; Bi, X.Y.; Gao, S.; Yan, T.D.; Zheng, G.D.; Chen, T.T.; Ye, J.T.; Liu, P.Q. EGCG inhibits pressure overload-induced cardiac hypertrophy via the PSMB5/Nmnat2/SIRT6-dependent signalling pathways. Acta Physiol. 2021, 231, e13602. [Google Scholar] [CrossRef] [PubMed]
  45. Liu, Y.; Gao, L.; Guo, S.; Liu, Y.; Zhao, X.; Li, R.; Yan, X.; Li, Y.; Wang, S.; Niu, X.; et al. Kaempferol alleviates angiotensin II-induced cardiac dysfunction and interstitial fibrosis in mice. Cell. Physiol. Biochem. 2017, 43, 2253–2263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Li, X.; Liu, J.; Wang, J.; Zhang, D. Luteolin suppresses lipopolysaccharide-induced cardiomyocyte hypertrophy and autophagy In Vitro. Mol. Med. Rep. 2019, 19, 1551–1560. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Zhang, S.; Wang, Y.; Yu, M.; Shang, Y.; Chang, Y.; Zhao, H.; Kang, Y.; Zhao, L.; Xu, L.; Zhao, X.; et al. Discovery of herbacetin as a novel SGK1 inhibitor to alleviate myocardial hypertrophy. Adv. Sci. 2022, 9, e2101485. [Google Scholar] [CrossRef] [PubMed]
Life 13 00043 g001 550
Figure 1. Effect of Parkia speciosa empty pod crude extract and fractions on H9c2 cardiomyocyte viability. The data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control (0 µg/mL), a p < 0.05 compared to chloroform 62.5 µg/mL, b p < 0.05 compared to chloroform 125 µg/mL, c p < 0.05 compared to n-hexane 125 µg/mL, d p < 0.05 compared to chloroform 125 µg/mL, e p < 0.05 compared to n-hexane 125 µg/mL, f p < 0.05 compared to chloroform 250 µg/mL, g p < 0.05 compared to crude 250 µg/mL, h p < 0.05 compared to chloroform 250 µg/mL.
Figure 1. Effect of Parkia speciosa empty pod crude extract and fractions on H9c2 cardiomyocyte viability. The data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control (0 µg/mL), a p < 0.05 compared to chloroform 62.5 µg/mL, b p < 0.05 compared to chloroform 125 µg/mL, c p < 0.05 compared to n-hexane 125 µg/mL, d p < 0.05 compared to chloroform 125 µg/mL, e p < 0.05 compared to n-hexane 125 µg/mL, f p < 0.05 compared to chloroform 250 µg/mL, g p < 0.05 compared to crude 250 µg/mL, h p < 0.05 compared to chloroform 250 µg/mL.
Life 13 00043 g001
Life 13 00043 g002 550
Figure 2. Effects of various concentrations (µg/mL) of P. speciosa empty pod crude extract and fractions, and valsartan (20 μM) on brain natriuretic peptide (BNP) in angiotensin II (Ang II)-induced cardiac hypertrophy in H9c2 cardiomyocytes. The data are expressed as means ± SEM. * p < 0.05 compared to control, # p < 0.05 compared to Ang II. EA, ethyl acetate. a p < 0.05 compared to crude 25 + Ang II, b p < 0.05 compared to EA 25 + Ang II, c p < 0.05 compared to methanol 25 + Ang II, d p < 0.05 compared to valsartan + Ang II.
Figure 2. Effects of various concentrations (µg/mL) of P. speciosa empty pod crude extract and fractions, and valsartan (20 μM) on brain natriuretic peptide (BNP) in angiotensin II (Ang II)-induced cardiac hypertrophy in H9c2 cardiomyocytes. The data are expressed as means ± SEM. * p < 0.05 compared to control, # p < 0.05 compared to Ang II. EA, ethyl acetate. a p < 0.05 compared to crude 25 + Ang II, b p < 0.05 compared to EA 25 + Ang II, c p < 0.05 compared to methanol 25 + Ang II, d p < 0.05 compared to valsartan + Ang II.
Life 13 00043 g002
Life 13 00043 g003 550
Figure 3. Total ion chromatogram of the ethyl acetate (EA) fraction of P. speciosa empty pods. 1, Gallic acid; 2, pantothenic acid; 3, 2′-2′-bisepigallocatechin monogallate; 4, theasinensin A; 5, picein; 6, thonningianin A; 7, 3,5,7,2′,6′-pentahydroxyflavone 2′-glucoside; 8, amaronol A; 9, quercetin 3′-glucoside; 10, quercetin 3-(6‴-sinapylglucosyl)(1->2)-galactoside; 11, spiraeoside; 12, kaempferol 3-alpha-D-galactoside; 13, 6-hydroxyluteolin 7-apioside; 14, gossypetin; 15, herbacetin; 16, bracteatin; 17, 3′-N-debenzoyl-2′-deoxytaxol; 18, glepidotin C; and 19, mayolene-16.
Figure 3. Total ion chromatogram of the ethyl acetate (EA) fraction of P. speciosa empty pods. 1, Gallic acid; 2, pantothenic acid; 3, 2′-2′-bisepigallocatechin monogallate; 4, theasinensin A; 5, picein; 6, thonningianin A; 7, 3,5,7,2′,6′-pentahydroxyflavone 2′-glucoside; 8, amaronol A; 9, quercetin 3′-glucoside; 10, quercetin 3-(6‴-sinapylglucosyl)(1->2)-galactoside; 11, spiraeoside; 12, kaempferol 3-alpha-D-galactoside; 13, 6-hydroxyluteolin 7-apioside; 14, gossypetin; 15, herbacetin; 16, bracteatin; 17, 3′-N-debenzoyl-2′-deoxytaxol; 18, glepidotin C; and 19, mayolene-16.
Life 13 00043 g003
Life 13 00043 g004 550
Figure 4. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on cell surface area in Ang II-induced cardiomyocyte hypertrophy. (a) Representative images from each group at 100× magnification and (b) relative cell surface area. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II.
Figure 4. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on cell surface area in Ang II-induced cardiomyocyte hypertrophy. (a) Representative images from each group at 100× magnification and (b) relative cell surface area. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II.
Life 13 00043 g004
Life 13 00043 g005 550
Figure 5. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on (a) protein content per cell (mg/million cells) and (b) ANP/GAPDH mRNA expression in Ang II-induced cardiomyocyte hypertrophy. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II, $ p < 0.05 compared to valsartan + Ang II, a p < 0.05 compared to 6.25 µg/mL EA + Ang II, b p < 0.05 compared to 12.5 µg/mL EA + Ang II.
Figure 5. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on (a) protein content per cell (mg/million cells) and (b) ANP/GAPDH mRNA expression in Ang II-induced cardiomyocyte hypertrophy. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II, $ p < 0.05 compared to valsartan + Ang II, a p < 0.05 compared to 6.25 µg/mL EA + Ang II, b p < 0.05 compared to 12.5 µg/mL EA + Ang II.
Life 13 00043 g005
Life 13 00043 g006 550
Figure 6. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on reactive oxygen species (ROS) in Ang II-induced cardiomyocyte hypertrophy. (a) Representative images from each treatment group and (b) ROS fluorescence intensity. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II.
Figure 6. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on reactive oxygen species (ROS) in Ang II-induced cardiomyocyte hypertrophy. (a) Representative images from each treatment group and (b) ROS fluorescence intensity. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II.
Life 13 00043 g006
Life 13 00043 g007 550
Figure 7. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on Ang II-induced NADPH oxidase 4 (Nox4) (a) protein expression and (b) immunofluorescent expression (green), while 4′,6-diamidino-2-phenylindole (DAPI) staining in blue indicates the nuclei in H9c2 cardiomyocytes. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II.
Figure 7. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on Ang II-induced NADPH oxidase 4 (Nox4) (a) protein expression and (b) immunofluorescent expression (green), while 4′,6-diamidino-2-phenylindole (DAPI) staining in blue indicates the nuclei in H9c2 cardiomyocytes. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II.
Life 13 00043 g007
Life 13 00043 g008 550
Figure 8. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on the Ang II-induced MAPK signaling pathway, namely (a) p-p38, (b) p-ERK 1/2, and (c) p-JNK, in H9c2 cardiomyocytes. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II, a p < 0.05 compared to EA at 6.25 µg/mL + Ang II.
Figure 8. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on the Ang II-induced MAPK signaling pathway, namely (a) p-p38, (b) p-ERK 1/2, and (c) p-JNK, in H9c2 cardiomyocytes. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II, a p < 0.05 compared to EA at 6.25 µg/mL + Ang II.
Life 13 00043 g008
Life 13 00043 g009 550
Figure 9. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on (a) p-GATA4 and (b) calcineurin protein expression and (c) NFATC3 gene expression in Ang II-induced cardiomyocyte hypertrophy. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II, a p < 0.05 compared to 6.25 + Ang II, b p < 0.05 compared to 12.5 + Ang II.
Figure 9. Effects of the EA fraction (µg/mL) of P. speciosa and valsartan (20 µM) on (a) p-GATA4 and (b) calcineurin protein expression and (c) NFATC3 gene expression in Ang II-induced cardiomyocyte hypertrophy. Data are expressed as means ± SEM (n = 3). * p < 0.05 compared to control, # p < 0.05 compared to Ang II, a p < 0.05 compared to 6.25 + Ang II, b p < 0.05 compared to 12.5 + Ang II.
Life 13 00043 g009
Life 13 00043 g010 550
Figure 10. Graphical summary of potential cardioprotective effects of ethyl acetate fraction of P. speciosa empty pod extract against key proteins involved in cardiac hypertrophy. Ang II, Angiotensin II; AT1R, angiotensin II type 1 receptor; ANP, A-type natriuretic peptide; BNP, B-type natriuretic peptide; NFAT, nuclear factor of activated T-cells; Nox4, NADPH oxidase 4; MAPKs, Mitogen-activated protein kinases; p-ERK1/2, phosphorylated extracellular signal-related kinase; p-JNK, phosphorylated c-Jun N-terminal kinase; p-p38, phosphorylated p38 kinase; ROS, reactive oxygen species.
Figure 10. Graphical summary of potential cardioprotective effects of ethyl acetate fraction of P. speciosa empty pod extract against key proteins involved in cardiac hypertrophy. Ang II, Angiotensin II; AT1R, angiotensin II type 1 receptor; ANP, A-type natriuretic peptide; BNP, B-type natriuretic peptide; NFAT, nuclear factor of activated T-cells; Nox4, NADPH oxidase 4; MAPKs, Mitogen-activated protein kinases; p-ERK1/2, phosphorylated extracellular signal-related kinase; p-JNK, phosphorylated c-Jun N-terminal kinase; p-p38, phosphorylated p38 kinase; ROS, reactive oxygen species.
Life 13 00043 g010
Table
Table 1. Metabolites identified from ethyl acetate fraction of P. speciosa empty pods by ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS/MS).
Table 1. Metabolites identified from ethyl acetate fraction of P. speciosa empty pods by ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS/MS).
NoRT
(min)		[M-H]−
(m/z)		m/zFormulaMS/MSTentative IdentificationClass of Compound
11.1169.0135170.0208C7 H6 O5125.0278Gallic acidPhenolic
22.108218.1041219.1114C9 H17 N O5146.0824Pantothenic acidAmino acid
32.879761.1266762.1431C37 H30 O18423.0714, 591.11162′-2′-Bisepigallocatechin monogallateFlavonoid
43.709913.1353914.1547C44 H34 O22177.0194, 285.0393, 423.0708, 591.1129, 743.1223Theasinensin AFlavonoid
54.132342.1058343.1041C14 H18 O7223.061PiceinPhenolic
64.585914.1601915.1514C42 H34 O21169.0148, 457.0770, 703.0976Thonningianin ATannin
77.096463.086464.0932C43 H32 O20300.0263,5,7,2′,6′-Pentahydroxyflavone 2′-glucosideFlavonoid glycoside
87.579319.0465320.0538C15 H12 O8167.0354Amaronol AFlavanoid
97.9777463.0893464.0963C21 H20 O12151.0032, 300.0278, 343.0461Quercetin 3′-glucosideFlavonoid glycoside
108.023831.1714832.2088C38 H40 O21300.0268, 463.0878Quercetin 3-(6‴-sinapylglucosyl)(1->2)-galactosideFlavonoid glycoside
118.155463.0887464.0958C21 H20 O12300.0276SpiraeosideFlavonoid glycoside
128.29
8.866
447.0935
448.1008
C21 H20 O11		301.0344
301.0346		Kaempferol 3-alpha-D-galactosideFlavonoid glycoside
138.341433.0779434.0851C20 H18 O11151.0031, 300.02766-Hydroxyluteolin 7-apiosideFlavonoid glycoside
148.794317.0305318.0378C15 H10 O8178.9982GossypetinFlavonoid
159.933301.0365302.0437C15 H10 O7121.0295, 151.0033, 178.9984, 229.0497HerbacetinFlavonoid
1610.365301.0359302.0431C15 H10 O7151.0032BracteatinFlavonoid
1714.735732.2692733.3104C40 H47 N O12160.01443′-N-Debenzoyl-2′-deoxytaxolTerpenoid
1817.39297.1499298.1569C19 H22 O3183.0101Glepidotin CFlavonoid
1924.398531.4415532.4486C34 H60 O4346.9493, 487.4492Mayolene-16Fatty acid
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mustafa, N.H.; Jalil, J.; Saleh, M.S.M.; Zainalabidin, S.; Asmadi, A.Y.; Kamisah, Y. Parkia speciosa Hassk. Empty Pod Extract Prevents Cardiomyocyte Hypertrophy by Inhibiting MAPK and Calcineurin-NFATC3 Signaling Pathways. Life 2023, 13, 43. https://doi.org/10.3390/life13010043

AMA Style

Mustafa NH, Jalil J, Saleh MSM, Zainalabidin S, Asmadi AY, Kamisah Y. Parkia speciosa Hassk. Empty Pod Extract Prevents Cardiomyocyte Hypertrophy by Inhibiting MAPK and Calcineurin-NFATC3 Signaling Pathways. Life. 2023; 13(1):43. https://doi.org/10.3390/life13010043

Chicago/Turabian Style

Mustafa, Nor Hidayah, Juriyati Jalil, Mohammed S. M. Saleh, Satirah Zainalabidin, Ahmad Yusof Asmadi, and Yusof Kamisah. 2023. "Parkia speciosa Hassk. Empty Pod Extract Prevents Cardiomyocyte Hypertrophy by Inhibiting MAPK and Calcineurin-NFATC3 Signaling Pathways" Life 13, no. 1: 43. https://doi.org/10.3390/life13010043

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop